Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 19 09 2023
accepted: 03 10 2023
medline: 24 11 2023
pubmed: 22 11 2023
entrez: 22 11 2023
Statut: epublish

Résumé

Since 72% of rare diseases are genetic in origin and mostly paediatrics, genetic newborn screening represents a diagnostic "window of opportunity". Therefore, many gNBS initiatives started in different European countries. Screen4Care is a research project, which resulted of a joint effort between the European Union Commission and the European Federation of Pharmaceutical Industries and Associations. It focuses on genetic newborn screening and artificial intelligence-based tools which will be applied to a large European population of about 25.000 infants. The neonatal screening strategy will be based on targeted sequencing, while whole genome sequencing will be offered to all enrolled infants who may show early symptoms but have resulted negative at the targeted sequencing-based newborn screening. We will leverage artificial intelligence-based algorithms to identify patients using Electronic Health Records (EHR) and to build a repository "symptom checkers" for patients and healthcare providers. S4C will design an equitable, ethical, and sustainable framework for genetic newborn screening and new digital tools, corroborated by a large workout where legal, ethical, and social complexities will be addressed with the intent of making the framework highly and flexibly translatable into the diverse European health systems.

Identifiants

pubmed: 37992053
doi: 10.1371/journal.pone.0293503
pii: PONE-D-23-26393
pmc: PMC10664952
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0293503

Informations de copyright

Copyright: © 2023 Garnier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

none.

Références

Orphanet J Rare Dis. 2022 Jun 18;17(1):233
pubmed: 35717227
Am J Hum Genet. 2019 Jan 3;104(1):76-93
pubmed: 30609409
Lancet Reg Health Eur. 2022 Jan 28;13:100311
pubmed: 35199083
Nat Rev Drug Discov. 2011 May;10(5):341-9
pubmed: 21532564
Orphanet J Rare Dis. 2022 Apr 12;17(1):163
pubmed: 35414039
Bull World Health Organ. 2008 Apr;86(4):317-9
pubmed: 18438522
Eur J Hum Genet. 2020 Feb;28(2):165-173
pubmed: 31527858
Front Med (Lausanne). 2021 Feb 02;8:593281
pubmed: 33604345
Nat Protoc. 2022 Jun;17(6):1415-1443
pubmed: 35411044
Orphanet J Rare Dis. 2018 Nov 6;13(1):196
pubmed: 30400963
Rare Dis. 2013 Jan 28;1:e23579
pubmed: 25002987
Nat Rev Drug Discov. 2020 Feb;19(2):77-78
pubmed: 32020066
J Allergy Clin Immunol. 2021 Feb;147(2):428-438
pubmed: 33551024

Auteurs

Nicolas Garnier (N)

Pfizer Inc., Collegeville, Pennsylvania, United States of America.

Joanne Berghout (J)

Pfizer Inc., Collegeville, Pennsylvania, United States of America.

Aldona Zygmunt (A)

Pfizer Inc., Collegeville, Pennsylvania, United States of America.

Deependra Singh (D)

Pfizer Inc., Collegeville, Pennsylvania, United States of America.

Kui A Huang (KA)

Pfizer Inc., Collegeville, Pennsylvania, United States of America.

Waltraud Kantz (W)

Pfizer Inc., Collegeville, Pennsylvania, United States of America.

Carl Rudolf Blankart (CR)

KPM Center for Public Management and Swiss Institute for Translational and Entrepreneurial Medicine, University of Bern, Bern, Switzerland.

Sandra Gillner (S)

KPM Center for Public Management and Swiss Institute for Translational and Entrepreneurial Medicine, University of Bern, Bern, Switzerland.

Jiawei Zhao (J)

Department of Mathematics and Computer Science, University of Southern Denmark, Odense, Denmark.

Richard Roettger (R)

Department of Mathematics and Computer Science, University of Southern Denmark, Odense, Denmark.

Christina Saier (C)

Department of Neuropediatric and Muscle Disorders, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Jan Kirschner (J)

Department of Neuropediatric and Muscle Disorders, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Joern Schenk (J)

Takeda Pharmaceuticals International AG, Opfikon, Switzerland.

Leon Atkins (L)

Takeda Pharmaceuticals International AG, Opfikon, Switzerland.

Nuala Ryan (N)

Takeda Pharmaceuticals International AG, Opfikon, Switzerland.

Kaja Zarakowska (K)

Takeda Pharmaceuticals International AG, Opfikon, Switzerland.

Jana Zschüntzsch (J)

Department of Neurology, University Medical Center Goettingen, Göttingen, Germany.

Michela Zuccolo (M)

F. Hoffmann La-Roche, Basel, Switzerland.

Matthias Müllenborn (M)

Novo Nordisk Health Care AG, Switzerland &Novo Nordisk A/S, Kloten, Denmark.

Yuen-Sum Man (YS)

Novo Nordisk Health Care AG, Switzerland &Novo Nordisk A/S, Kloten, Denmark.

Liz Goodman (L)

University College Dublin, National University of Ireland, Dublin, Ireland.

Marie Trad (M)

Lysogene, Neuilly-sur-Seine, France.

Anne Sophie Chalandon (AS)

Sanofi, Diegem, Belgium.

Stefaan Sansen (S)

Sanofi, Diegem, Belgium.

Maria Martinez-Fresno (M)

Illumina, Cambridge, United Kingdom.

Shirlene Badger (S)

Illumina, Cambridge, United Kingdom.

Rudolf Walther van Olden (R)

Novartis Gene Therapies Switzerland GmbH, Risch-Rotkreuz, Switzerland.

Robert Rothmann (R)

Research Institute AG & Co KG, Digital Human Rights Center, Wien, Austria.

Patrick Lehner (P)

Research Institute AG & Co KG, Digital Human Rights Center, Wien, Austria.

Christof Tschohl (C)

Research Institute AG & Co KG, Digital Human Rights Center, Wien, Austria.

Ludovic Baillon (L)

PTC Therapeutics Switzerland GmbH, Steinhausen, Switzerland.

Gulcin Gumus (G)

EURORDIS, Paris, France.

Edith Gross (E)

EURORDIS, Paris, France.

Rumen Stefanov (R)

Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria.
Bulgarian Association for Promotion of Education and Science, Institute for Rare Disease, Plovdiv, Bulgaria.

Georgi Iskrov (G)

Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria.
Bulgarian Association for Promotion of Education and Science, Institute for Rare Disease, Plovdiv, Bulgaria.

Ralitsa Raycheva (R)

Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria.
Bulgarian Association for Promotion of Education and Science, Institute for Rare Disease, Plovdiv, Bulgaria.

Kostadin Kostadinov (K)

Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria.
Bulgarian Association for Promotion of Education and Science, Institute for Rare Disease, Plovdiv, Bulgaria.

Elena Mitova (E)

Bulgarian Association for Promotion of Education and Science, Institute for Rare Disease, Plovdiv, Bulgaria.

Moshe Einhorn (M)

Genoox, Tel Aviv, Israel.

Yaron Einhorn (Y)

Genoox, Tel Aviv, Israel.

Josef Schepers (J)

Berlin Institute of Health (at) Charité - Universitätsmedizin Berlin, Berlin, Germany.

Miriam Hübner (M)

Berlin Institute of Health (at) Charité - Universitätsmedizin Berlin, Berlin, Germany.

Frauke Alves (F)

Translational Molecular Imaging, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Clinic of Hematology and Medical Oncology, University Medical Center, Göttingen, Germany.
Institute for Diagnostic and Interventional Radiology, University Medical Center, Göttingen, Germany.

Rowan Iskandar (R)

Swiss Institute for Translational and Entrepreneurial Medicine (sitem-insel), Bern, Switzerland.

Rudolf Mayer (R)

SBA Research gGmbH, Wien, Austria.

Alessandra Renieri (A)

Medical Genetics, University of Siena, Siena, Italy.

Aneta Piperkova (A)

Bulgarian Association for Personalized Medicine, Sofia, Bulgaria.

Ivo Gut (I)

Centro Nacional de Analisis Genomico, CNAG, Barcelona, Spain.

Sergi Beltran (S)

Centro Nacional de Analisis Genomico, CNAG, Barcelona, Spain.

Mads Emil Matthiesen (ME)

FindZebra APS, Copenhagen, Denmark.

Marion Poetz (M)

Department of Strategy and Innovation, Copenhagen Business School, Copenhagen, Denmark.

Mats Hansson (M)

Uppsala University, Uppsala, Sweden.

Regina Trollmann (R)

University of Erlangen, Erlangen, Germany.

Emanuele Agolini (E)

Bambino Gesu' Children Hospital, IRCCS, Rome, Italy.

Silvia Ottombrino (S)

Bambino Gesu' Children Hospital, IRCCS, Rome, Italy.

Antonio Novelli (A)

Bambino Gesu' Children Hospital, IRCCS, Rome, Italy.

Enrico Bertini (E)

Bambino Gesu' Children Hospital, IRCCS, Rome, Italy.

Rita Selvatici (R)

Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Marianna Farnè (M)

Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Fernanda Fortunato (F)

Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Alessandra Ferlini (A)

Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH